Zobrazeno 1 - 7
of 7
pro vyhledávání: '"B. A. Dusak"'
Autor:
A. Yayon, Kristi Eidsvoog, P. Czerniak, Janet L. Gross, Daniel L. Dexter, B. A. Dusak, M. D. Diamond, T. Sun, William F. Herblin
Publikováno v:
JNCI: Journal of the National Cancer Institute. 85:121-131
Background Recombinant human basic fibroblast growth factor (rHu-bFGF) is known to stimulate proliferation in some tumor cells and to modulate tumor vascularization. Purpose The purpose of this study was to examine the possible role of this agent in
Autor:
S F Chen, D L Behrens, C H Behrens, P M Czerniak, D L Dexter, B L Dusak, J R Fredericks, K C Gale, J L Gross, J B Jiang, Kirshenbau m, R J McRipley, L M Papp, A D Patten, F W Perrella, S P Seitz, M P Stafford, J H Sun, T Sun, M A Wuonola, DD Von Hoff
Publikováno v:
Anti-cancer drugs. 4(4)
We have synthesized a promising class of bis-naphthalimide anti-tumor agents. A representative compound in this series, XB596, exhibits potent in vitro growth inhibitory activity against several human and murine leukemic and solid tumor lines in cult
Publikováno v:
ChemInform. 21
A novel series of 2-styrylquinazolin-4(3H-ones which inhibited tubulin polymerization and the growth of L1210 murine leukemia cells was discovered. Extensive structure-activity relationship studies suggest that the entire quinazolinone structure was
Publikováno v:
Journal of medicinal chemistry. 33(6)
A novel series of 2-styrylquinazolin-4(3H-ones which inhibited tubulin polymerization and the growth of L1210 murine leukemia cells was discovered. Extensive structure-activity relationship studies suggest that the entire quinazolinone structure was
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 253(1)
Brequinar is a developmental antitumor agent which is highly bound to plasma proteins. The effects of plasma protein binding displacement on brequinar pharmacokinetics, tissue distribution, tumor distribution and antitumor efficacy were evaluated. So
Autor:
D L, Dexter, D P, Hesson, R J, Ardecky, G V, Rao, D L, Tippett, B A, Dusak, K D, Paull, J, Plowman, B M, DeLarco, V L, Narayanan
Publikováno v:
Cancer research. 45(11 Pt 1)
A novel, substituted 4-quinolinecarboxylic acid (NSC 339768) demonstrated antitumor activity against L1210 leukemia and B16 melanoma in the National Cancer Institute's Developmental Therapeutics Program. An extensive analogue synthesis program was in
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 121(6)